Contact Us

Phone 1300 884 450

Our Medical Advisory Committee

Victoria Atkinson

Dr. Victoria Atkinson

Dr. Victoria Atkinson is a Senior Staff Specialist Medical Oncologist at the Princess Alexandra Hospital since 2007 and Visiting Medical Oncologist at Greenslopes Private Hospital since 2011.

Her undergraduate training was undertaken at the University of Queensland and she completed her FRACP in Medical Oncology in 2006. Her tumour interests include Melanoma and Gastro-intestinal tumours.

She has extensive experience with targeted therapies for Melanoma including Vemurafenib, Dabrafenib, Trametinib and Ipilimumab, Nivolumab and Pembrolizumab and is involved in clinical trials with these therapies at both sites.

Read More
Johnathan Cebon

Professor Jonathan Cebon

MBBS, PhD, FRACP
Jonathan Cebon is the Medical Director of the Cancer Services Unit at the Olivia Newton-John Cancer & Wellness Centre (ONJCWC) at Austin Health in Heidelberg Victoria.

He is also the Medical Director of the Olivia Newton-John Cancer Research Institute. His clinical area of interest is the immune therapy of cancer.

He is a Professor in Medicine at the University of Melbourne and Fellow of the Royal Australasian College of Physicians. He is a lead investigator in the Victorian Cancer Agency funded Melbourne Melanoma Project. He serves on the Cancer Council of Victoria and has served as a member of the Consultative Council of the Victorian Cancer Agency. He serves on the Scientific Committee of the Cancer Vaccine Collaborative (CVC), an organisation that plays a major international role supporting basic, translational and clinical research into the immune therapy of cancer.

As a lead investigator for Ludwig Institute for Cancer Research (LICR) and CVC in Australia for 20 years he has led more than 20 immunotherapy Phase I and II clinical trials and translational projects with immunotherapeutics.

Read More
Georgina Long

Professor Georgina Long

BSc PhD MBBS FRACP
Professor Georgina Long, is Chair of Melanoma Medical Oncology and Translational Research at Melanoma Institute Australia & Royal North Shore Hospital, The University of Sydney.

She leads an extensive clinical trials team and laboratory at MIA, with a focus on targeted therapies and immuno-oncology in melanoma. She is principal investigator on phase I, II and III clinical trials in adjuvant and metastatic melanoma, including trials in patients with active brain metastases.

She is the chief investigator on NHMRC funded research into the molecular biology of melanoma, with a particular interest in clinical and tissue biomarker correlates of systemic therapy sensitivity and resistance. In recognition of her ground breaking research, Professor Long has received a number of awards, including the prestigious Sir Zelman Cowen Universities Fund Prize for Discovery in Medical Research in 2016, and a number of recent CINSW Premier’s Awards for Outstanding Cancer Research: In 2014, she was awarded the Wildfire Award for the most highly-cited, original, peer-reviewed article published in 2011; and in 2013 she was named the Outstanding Cancer Research Fellow. She is the author of over 125 peer-reviewed publications in clinical and translational research in melanoma since 2011, including the New England Journal of Medicine, Lancet, Lancet Oncology, Journal of Clinical Oncology and Cancer Discovery. Professor Long has presented her work at international conferences and meetings on more than 120 occasions.

She is Chair of the ASCO Scientific Committee for melanoma and skin cancer, is medical oncology lead for the Australian Melanoma Management Guidelines Committee, is on the editorial boards of several high-impact journals, and is a member of the Melanoma Expert Panel for AJCC Cancer Staging System 8th edition.

Professor Long was awarded the University Medal in Organic Chemistry. She subsequently completed her PhD in Chemistry in the field of anti-cancer agents and their binding to DNA. She then moved to the USA to take up a Fulbright Postdoctoral Fellowship at Scripps Research Institute, exploring nanotechnology in cancer treatment, before returning to Australia to complete her MBBS (Hons). Professor Long became a Fellow of the Australasian College of Physicians in January 2008, specialising in medical oncology.

Read More
Grant MacArthur

Professor Grant McArthur

Professor Grant McArthur is a Fellow of the Royal Australasian College of Physicians and holds a Ph.D. in Medical Biology. He has been appointed the inaugural Lorenzo Galli chair position in Melanoma, University of Melbourne.

He is also Co-Head Cancer Therapeutics and Practitioner Fellow NHMRC.

In 2004 he was awarded the Translational Research Award of the Foundation Nelia et Amadeo Barletta and presented a plenary paper at the EORTC-NCI-ACCR Symposium on Molecular Targets and Cancer Therapeutics.

In 2005 he was awarded the Sir Edward Dunlop Clinical Cancer Research Fellowship of the Cancer Council of Victoria. He is national and international study Co-Chair of a number of clinical trials of targeted therapies. His research Interests include clinical trials of targeted therapeutics, personalised medicine, melanoma, cell cycle control, and functional imaging. Professor McArthur is on the Editorial Board for melanoma at Annals of Oncology and sits on the editorial board of Anti-Cancer Drugs, the Journal of Clinical Oncology, the Open Clinical Cancer Journal, Therapeutic Advances in Medical Oncology and the Journal of Personalised Medicine. He has had over 175 publications including senior or first author publications in the following journals: New England Journal of Medicine, Journal of Clinical Oncology, Lancet Oncology, Cancer Discovery, Cancer Cell, Nature, Cell Biology, Blood and EMBO.

Read More
Mark Smithers

Professor Mark Smithers

  • University of Queensland – Bachelor of Medicine, Bachelor of Surgery 1977
  • Fellow of the Royal Australasian College of Surgeons 1985
  • Fellow of the Royal College of Surgeons of England 1986
  • Fellow, Royal College of Surgeons of Edinburgh (Ad Hom) 2012
  • Mayne Professor, Head of Discipline of Surgery, University of Queensland
  • Director, Upper Gastro-intestinal and Soft Tissue Unit, Princess Alexandra Hospital.
  • Chairman, Queensland Melanoma Project
  • Director, Melanoma Patients Australia

Melanoma interests:
Surgeon involved in the management of patients with all stages of melanoma for 26 years.

Senior surgeon at the Melanoma Clinic at the Princess Alexandra Hospital.

Research involvement:
Epidemiology of melanoma in Queensland – Collaboration with the Queensland Institute of Medical Research, Epidemiology Unit.

Assessment of the outcomes of patients with high risk primary and secondary melanoma.

Phase I-III trials in the surgical and medical management of patients with stage III and IV melanoma. These include locally based studies as well as collaboration in national and international trials.

Read More
Peter Soyer

Professor Peter Soyer

Head, South-West Clinical Cluster Deputy Head, School of Medicine Chair, Dermatology Research Centre, The University of Queensland. Professor Peter Soyer has a dual role within the University of Queensland.

He is the Head of the South-West Clinical Cluster & Deputy Head of the School of Medicine, and the inaugural Chair and Director of the Dermatology Research Centre at the Translational Research Institute. He is also Director of the Dermatology Department at the Princess Alexandra Hospital.

Professor Soyer, an academic dermatologist from Austria, is a world leader in the field of dermatology with particular expertise in the areas of clinical dermatology, dermatooncology, dermatopathology and dermatologic imaging (dermoscopy and reflectance confocal microscopy).

His research group’s main focus is skin cancer (both non-melanoma skin cancer and melanoma), and he is co-inventor in multiple patents for novel skin delivery platforms and microbiospy sampling devices. He has an extensive publication record with over 600 publications to date (more than 150 publications in the last 5 years) and more than 550 citations a year (in the last 5 years) and a Hirsch index of 63 (Google Scholar). He is past President of the International Society of Dermoscopy and the International Society of Teledermatology and is co-editor in chief of the Australasian Journal of Dermatology. He is lead investigator of the Centre of Research Excellence for the Study of Naevi awarded in December 2015, funded by the Australian Government National Health and Medical Research Council (NHMRC).

Read More
Jane Turner

Professor Jane Turner

MBBS, PhD, FRANZCP
Professor Jane Turner is a consultation-liaison psychiatrist who has worked clinically for over 25 years in psycho-oncology. She treats patients with diverse cancer diagnoses & disease stages.

However, she has a particular interest in Stage III and IV melanoma including the impact on families, and ways of assisting parents to talk with their dependent children.

She is serving a second term on the Board of the International Psycho-Oncology Society (IPOS), the peak international body promoting psycho-oncology, Chairs the Guidelines Committee, and is Co-Chair of the WHO Committee of IPOS which has developed a comprehensive program to enhance the status of psychosocial care globally, with a focus on education and capacity-building in low-to middle-income countries. She is a member of the Scientific Advisory Committee of the Psycho-oncology Cooperative Research Group, a member of the Cancer Australia Breast Cancer Advisory Group and Scientific Advisor to Breast Cancer Network of Australia.

She has been extensively involved in educational initiatives to enhance the confidence and skills of health professionals in providing psychosocial care for people affected by cancer. Her research interests include evaluation of innovative models of psychosocial care provided by front-line health professionals, and promotion of wellness for cancer survivors. She was a member of the Clinical Oncology Society of Australia Working Group that developed the COSA Model of Survivorship Care, launched in 2016. She has recently completed a trial of a nurse-delivered survivorship intervention for patients treated for head and neck cancer. She is an investigator in a multi-site trial of a manual-based psychosocial intervention for patients with breast, colorectal cancer and melanoma with high fear of cancer recurrence.

Read More

Sign up for Email Newsletter

Our quarterly e-newsletter includes the latest news, upcoming events and more.